Salarius Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue	0	0	1.84	5.23	3.47	1.95	1.85	1.01	0
Revenue Growth (YoY)	-	-	-64.84%	51.03%	77.57%	5.37%	83.24%	-	-
Cost of Revenue	0	0	0	0	0	0	0	0.66	0
Gross Profit	0	0	1.84	5.23	3.47	1.95	1.85	0.35	0
Selling, General & Admin	5.72	7.14	6.1	6.11	7.71	2.35	1.47	19.86	16.46
Research & Development	7.17	15.84	8.55	6.91	4.02	1.29	2.13	20.38	12.75
Other Operating Expenses	0	8.87	0	0	0	0	0	0	0
Operating Expenses	12.89	31.84	14.65	13.02	11.73	3.64	3.6	40.23	29.21
Operating Income	-12.89	-31.84	-12.81	-7.79	-8.27	-1.68	-1.75	-39.89	-29.21
Interest Expense / Income	0	0	0	0	-0.02	0	0	0	0
Other Expense / Income	-0.35	-0.23	-0.04	-0.43	-1.31	-0.01	-0	-0.39	-0.07
Pretax Income	-12.54	-31.61	-12.77	-7.35	-6.94	-1.67	-1.75	-39.49	-29.14
Net Income	-12.54	-31.61	-12.77	-7.35	-6.94	-1.67	-1.75	-39.49	-29.14
Preferred Dividends	0	0	0	0.4	0	0.12	0.09	0	0
Net Income Common	-12.54	-31.61	-12.77	-7.75	-6.94	-1.67	-1.84	-39.49	-29.14
Shares Outstanding (Basic)	3	2	2	1	0	0	0	0	0
Shares Outstanding (Diluted)	3	2	2	1	0	0	0	0	0
Shares Change	53.66%	28.40%	165.53%	376.61%	112.33%	34.15%	76.72%	15.68%	-
EPS (Basic)	-3.84	-14.88	-7.72	-12.50	-53.00	-29.00	-40.00	-1518.75	-1300.00
EPS (Diluted)	-3.84	-14.88	-7.72	-12.50	-53.00	-29.00	-40.00	-1518.75	-1300.00
Free Cash Flow	-12.85	-17.6	-10.2	-10.31	-11.58	4.18	-1.46	-32.61	-21.01
Free Cash Flow Per Share	-3.94	-8.28	-6.17	-16.55	-88.57	67.84	-31.73	-1255.32	-935.82
Gross Margin	-	-	100.00%	100.00%	100.00%	100.00%	100.00%	34.42%	-
Operating Margin	-	-	-696.27%	-148.78%	-238.53%	-86.33%	-94.44%	-3946.54%	-
Profit Margin	-	-	-693.84%	-148.06%	-200.18%	-85.56%	-99.36%	-3907.65%	-
Free Cash Flow Margin	-	-	-554.29%	-197.08%	-334.20%	214.07%	-78.63%	-3226.22%	-
EBITDA	-12.53	-31.6	-12.75	-7.33	-6.82	-1.65	-1.73	-39.22	-29.09
EBITDA Margin	-	-	-692.80%	-140.14%	-196.95%	-84.69%	-93.44%	-3880.21%	-
Depreciation & Amortization	0.01	0.01	0.02	0.02	0.13	0.02	0.02	0.28	0.05
EBIT	-12.54	-31.61	-12.77	-7.35	-6.95	-1.67	-1.75	-39.49	-29.14
EBIT Margin	-	-	-693.84%	-140.49%	-200.63%	-85.56%	-94.35%	-3907.65%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).